Reaching the cyclosporine a level target slowly in four weeks correlates with better prognosis for Chinese patients after allogeneic haematopoietic cell transplantation

References

• Martino R, Valcarcel D, Brunet S, et al. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission[J]. Bone Marrow Transplant. 2008;41(1):33–38. doi:10.1038/sj.bmt.1705879
   PubMed Web of Science ®Google Scholar
• Valcárcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival[J]. J Clin Oncol. 2008;26(4):577–584. doi:10.1200/JCO.2007.11.1641
   PubMed Web of Science ®Google Scholar
• Melve GK, Ersvaer E, Kittang AO, et al. The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?[J]. Expert Rev Hematol. 2011;4(5):563–576. doi:10.1586/ehm.11.54
   PubMed Web of Science ®Google Scholar
• Kanda Y, Hyo R, Yamashita T, et al. Effect of blood CsA concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor[J]. Am J Hematol. 2006;81(11):838–844. doi:10.1002/ajh.20710
   PubMed Web of Science ®Google Scholar
• Oshima K, Kanda Y, Nakasone H, et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level[J]. Am J Hematol. 2008;83(3):226–232. doi:10.1002/ajh.21087
   PubMed Web of Science ®Google Scholar
• Malard F, Szydlo RM, Brissot E, et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(1):28–34. doi:10.1016/j.bbmt.2009.08.010
   PubMed Web of Science ®Google Scholar
• Martin P, Bleyzac N, Souillet G, et al. Clinical and pharmacological risk factors for acute graftversus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant. 2003;32(9):881–887. doi:10.1038/sj.bmt.1704239
   PubMed Web of Science ®Google Scholar
• Martin P, Bleyzac N, Souillet G, et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant. 2003;32(8):777–784. doi:10.1038/sj.bmt.1704213
   PubMed Web of Science ®Google Scholar
• Huang X, Wu D. Chinese expert consensus on allogeneic hematopoietic stem cell transplantation for hematological diseases(Ⅲ) – Acute graft versus host disease (2020 version)[J]. Chin J Hematol. 2020;41(7):529–536.
   Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204–217. doi:10.1016/0002-9343(80)90380-0
   PubMed Web of Science ®Google Scholar
• Rogosheske JR, Fargen AD, DeFor TE, et al. Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival[J]. Bone Marrow Transplant. 2014;49(1):122–125. doi:10.1038/bmt.2013.139
   PubMed Web of Science ®Google Scholar
• Stocker N, Duléry R, Battipaglia G, et al. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation[J]. Eur J Haematol. 2019;103(1):10–17. doi:10.1111/ejh.13233
   PubMed Web of Science ®Google Scholar
• García Cadenas I, Valcarcel D, Martino R, et al. Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation[J]. Mediat Inflamm. 2014;2014:1–7.
   Web of Science ®Google Scholar
• Yang X, Yang S, Sun A, et al. Impact of cyclosporine-A concentration in T-cell replete haploidentical allogeneic stem cell transplantation. Clin Transplant. 2018;32(4):e13220. doi:10.1111/ctr.13220
   PubMed Web of Science ®Google Scholar
• Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation[J]. The Lancet Haematology. 2020;7(2):e157–e167. doi:10.1016/S2352-3026(19)30256-X
   PubMed Web of Science ®Google Scholar
• Kedmi M, Dray L, Grisariu S, et al. The effect of cyclosporine initiation time on the outcome of matched allogeneic stem-cell transplantation following fludarabine-based conditioning[J]. Transpl Int. 2012;25(12):1241–1247. doi:10.1111/j.1432-2277.2012.01559.x
   PubMed Web of Science ®Google Scholar
• Tang HL, Ma LL, Xie HG, et al. Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis[J]. Pharmacogenet Genomics. 2010;20(9):525–531. doi:10.1097/FPC.0b013e32833ccd56
   PubMed Web of Science ®Google Scholar
• Lee JS, Cheong HS, Kim LH, et al. Screening of genetic polymorphisms of CYP3A4 and CYP3A5 genes[J]. The Korean J Physiol Pharmacol: Official J Korean Physiol Soc Korean Soc Pharmacol. 2013;17(6):479. doi:10.4196/kjpp.2013.17.6.479
   PubMed Web of Science ®Google Scholar
• Li DY, Teng RC, Zhu HJ, et al. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients [J]. Int J Clin Pharmacol Ther. 2013;51(6):466–474. doi:10.5414/CP201836
   PubMed Web of Science ®Google Scholar
• Li Y, Hu X, Cai B, et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transpl Immunol. 2012;27:12–18. doi:10.1016/j.trim.2012.03.006
   PubMed Web of Science ®Google Scholar
• Lee J, Wang R, Yang Y, et al. The effect of ABCB 1 C 3435 T polymorphism on cyclosporine dose requirements in kidney transplant recipients: a meta-analysis[J]. Basic Clin Pharmacol Toxicol. 2015;117(2):117–125. doi:10.1111/bcpt.12371
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Labopin M, Bacigalupo A, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide[J]. Cancer. 2018;124(7):1428–1437. doi:10.1002/cncr.31228
   PubMed Web of Science ®Google Scholar